Business context and reporting period
The supplied filing is Organovo Holdings, Inc.’s Form 10-Q for the quarter and six months ended September 30, 2016 (fiscal 2017 second quarter), not a filing identified as Vivosim Labs, Inc. Organovo is an early-commercial-stage developer of 3D-bioprinted human tissues and related research services. Its commercial offerings include ExVive Human Liver Tissue; it began commercial contracting for ExVive Human Kidney Tissue in September 2016.
Financial performance and position
Amounts below are in U.S. dollars; financial statement figures are in thousands except per-share data.
| Metric | Three months ended Sep. 30, 2016 | Six months ended Sep. 30, 2016 | Prior-year comparison |
|---|---|---|---|
| Revenue | $1.376 million | $2.266 million | $0.301 million and $0.607 million, respectively |
| Cost of revenue | $0.393 million | $0.561 million | Immaterial; included in R&D expense |
| Operating loss | $9.479 million | $18.256 million | $11.284 million and $19.742 million, respectively |
| Net loss | $9.442 million | $18.209 million | $11.257 million and $19.748 million, respectively |
| Basic and diluted loss per share | $0.10 | $0.20 | $0.12 and $0.23, respectively |
Quarterly revenue rose about 358%; first-half revenue rose about 274%. Product and service revenue was $1.023 million for the quarter and $1.697 million for six months. Calculated gross margin was approximately 71% for the quarter and 75% for the six months, based on reported revenue less cost of revenue. R&D expense was $4.544 million for the quarter and $8.987 million for six months; selling, general and administrative expense was $5.918 million and $10.974 million, respectively.
At September 30, cash and cash equivalents were $51.723 million, down from $62.091 million at March 31. Working capital was $49.5 million, versus $59.2 million. Six-month operating cash use was $14.909 million; investing cash use was $0.452 million; financing provided $5.000 million. The balance sheet reports no borrowings; operating lease obligations totaled $5.478 million. Accumulated deficit was $179.079 million.
Material changes and notable items
- Revenue growth reflected adoption of liver-tissue research products and services and increased collaboration revenue, including milestone-related revenue. Grant revenue declined year over year as a significant grant had been completed.
- Quarterly SG&A fell 14%, mainly because the prior-year period included non-recurring costs related to two departed executives and higher consulting costs. R&D was nearly flat year over year as increased staffing was offset by lower consulting and lab-supply costs.
- On October 25, 2016, after quarter-end, Organovo completed an underwritten sale of 10.065 million shares for approximately $25.6 million net proceeds. Management stated that cash resources and its operating plan would fund operations for at least the next twelve months.
- The company announced plans in October 2016 to develop bioprinted human liver tissue for potential transplantation, following promising preclinical animal-study results. This remains a development program, not an established commercial product.
- Management reported disclosure controls were effective and no material change in internal control over financial reporting. No material change to previously disclosed risk factors was reported.
Outlook, risks and contingencies
No quantified revenue or earnings guidance was provided. Management’s stated runway assessment depends on its current operating plan; future capital needs depend on commercialization revenue and development spending. The company cautioned that additional financing may not be available on favorable terms and that equity financing could dilute shareholders. It also warned that inadequate financing could require reducing or delaying programs and could adversely affect its ability to continue as a going concern.
The company had no recorded accrual for legal contingencies and did not identify a probable or reasonably estimable loss, while noting that litigation outcomes are uncertain. Operating leases, including facility commitments, are a material contractual obligation. Commercial revenue remains concentrated among a relatively small number of customers and collaborators.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is for Organovo Holdings, Inc., despite the request metadata naming Vivosim Labs, Inc.
- Reconcile share counts: the filing reports 93,750,862 shares outstanding at September 30 and 10,065,000 shares issued in the October offering; it separately states 103,865,862 shares outstanding as of November 1. Those figures do not reconcile arithmetically, so verify the reported count and any intervening share issuances.
- Assess cash runway using the post-quarter-end offering proceeds, operating cash burn, and the company’s planned development and commercialization spending.
- Evaluate the sustainability and composition of revenue growth, including collaboration milestones, customer concentration, and the early commercial status of kidney-tissue services.
- Consider dilution from outstanding options, warrants, restricted stock units, the employee stock purchase plan, and future financing needs.